• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulin management software wins FDA nod

June 22, 2017 By Sarah Faulkner

Insulin AlgorithmsInsulin Algorithms said today that its decision-support software, designed to help clinicians manage insulin for patients with diabetes, won FDA clearance.

The company’s software allows clinicians to analyze a patient’s blood sugar measurements regularly and develop an optimized plan for the patient’s insulin regimen. The software was developed with algorithms that are clinically proven to lower blood sugar, according to the company.

Insulin Algorithms’ software also has CE Mark clearance, so it is approved for sale in both the U.S. and Europe.

More than half of patients with diabetes in the U.S. fail to meet the American Diabetes Association’s recommended blood glucose target, the company said.

“Think of the tiny percentage of people who keep their New Year’s resolutions, and then ask yourself how realistic it is to expect millions of diabetic patients to make lifelong behavioral changes,” CEO Josh Davidson said in prepared remarks. “Because of the shortage of endocrinologists, 90% of patients see their primary care provider for diabetes care. This results in a 6- to 7-year delay in the initiation of insulin and elevated blood sugar levels once patients are prescribed insulin. We designed our software to close this clinical care gap.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Technology Tagged With: insulinalgorithms

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS